Seres Therapeutics(DE:1S90)
€1.49-0.15 (-9.38%)
DE:1S90
Seres Therapeutics ownership
€1.49
At close:-0.15 (-9.38%)
Seres Therapeutics (1S90) Ownership - Who Owns Seres Therapeutics?
1 Followers
Seres Therapeutics (1S90) Ownership Overview
- 1.42% Insiders
- 4.27% Mutual Funds
- 0.01% Other Institutional Investors
- 3.45% ETFs
- 90.85% Public Companies and Individual Investors
The ownership structure of Seres Therapeutics (DE:1S90) stock is a mix of institutional, retail, and individual investors. Approximately 7.73% of the company’s stock is owned by Institutional Investors, 1.42% is owned by Insiders, and 90.85% is owned by Public Companies and Individual Investors.
The ownership structure of Seres Therapeutics (DE:1S90) stock is a mix of institutional, retail, and individual investors. Approximately 7.73% of the company’s stock is owned by Institutional Investors, 1.42% is owned by Insiders, and 90.85% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Noubar Afeyan | 1,155,850 | Institution | 11.34% | 1,908,308 |
| Vanguard | 282,019 | Institution | 2.77% | 465,613 |
| Vanguard Index Funds | 282,019 | Institution | 2.77% | 465,613 |
| BlackRock, Inc. | 111,000 | Institution | 1.09% | 183,261 |
| Fidelity Concord Street Trust | 63,579 | Institution | 0.62% | 104,969 |
| Richard Kender | 63,492 | Insider | 0.62% | 104,825 |
| Northern Funds | 33,558 | Institution | 0.33% | 55,404 |
| Willard Dere | 31,746 | Insider | 0.31% | 52,413 |
| Goldman Sachs Trust | 23,396 | Institution | 0.23% | 38,627 |
| Ishares | 23,051 | Institution | 0.23% | 38,057 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 282,019 | Institution | 2.77% | 465,613 |
| Fidelity Concord Street Trust | 63,579 | Institution | 0.62% | 104,969 |
| Northern Funds | 33,558 | Institution | 0.33% | 55,404 |
| Goldman Sachs Trust | 23,396 | Institution | 0.23% | 38,627 |
| Victory Portfolios Iii | 10,469 | Institution | 0.10% | 17,284 |
| Dfa Investment Dimensions Group Inc | 7,662 | Institution | 0.08% | 12,650 |
| Bridgeway Funds, Inc. | 7,500 | Institution | 0.07% | 12,383 |
| Vanguard Valley Forge Funds | 4,386 | Institution | 0.04% | 7,241 |
| Vanguard Institutional Index Funds | 1,371 | Institution | 0.01% | 2,264 |
| American Century Etf Trust | 1,176 | Institution | 0.01% | 1,942 |
FAQ
Who Owns Seres Therapeutics (DE:1S90)?
According to the latest TipRanks data, approximately 7.73% of the company's stock is held by institutional investors, 1.42% is held by insiders, and 90.85% is held by public companies and individual investors.
What percentage of Seres Therapeutics (DE:1S90) stock is held by institutional investors?
According to the latest TipRanks data, approximately 7.73% of Seres Therapeutics (DE:1S90) stock is held by institutional investors: 4.27% by mutual funds, 3.45% by ETFs and 0.01% by other institutional investors.
What percentage of Seres Therapeutics (DE:1S90) stock is held by retail investors?
According to the latest TipRanks data, approximately 90.85% of Seres Therapeutics (DE:1S90) stock is held by public companies and individual investors.
Who owns the most shares of Seres Therapeutics (DE:1S90)?
Noubar Afeyan owns the most shares of Seres Therapeutics (DE:1S90).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
